Rita Zhou

Immunology and Microbiology · Life Sciences

6h-index442citations15works26.32yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(9), Cancer Immunotherapy and Biomarkers(5), Monoclonal and Polyclonal Antibodies Research(4), Cancer Genomics and Diagnostics(3), vaccines and immunoinformatics approaches(3)

Publications15 total

A novel HLA Class II presentation prediction algorithm deciphers immunogenic CD4 epitopes specific to KRAS G12C
2024Open Access
Comprehensive Longitudinal ctDNA Monitoring in Metastatic Cancer Patients Treated with an Individualized Neoantigen-directed Vaccine
2024Open Access
5 Oral: Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer - NCT06179069
European Journal of Cancer·2024· 5 cited
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Nature Medicine·2024· 100 cited
Abstract 1126: Disease monitoring with comprehensive genomics provides evidence of mechanism of action and immune evasion in patients receiving an individualized neoantigen cancer vaccine
Cancer Research·2023
Abstract 2267: HLA-DR-restricted CD4 T cell responses to KRAS G12C in healthy donors linked to bacterial mimotope: lessons for KRAS neoantigen vaccines in cancer patients
Cancer Research·2023
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Nature Medicine·2022· 206 citedOpen Access
Abstract 1238: Comprehensive ctDNA monitoring provides early signal of clinical benefit with a novel personalized neoantigen directed immunotherapy for late-stage cancer patients
Cancer Research·2022· 1 cited
Abstract 4059: Identification of pre-existing neoantigen-specific T cells in patients receiving checkpoint inhibitor therapy using a deep learning antigen prediction model
Cancer Research·2019
Abstract 4059: Identification of pre-existing neoantigen-specific T cells in patients receiving checkpoint inhibitor therapy using a deep learning antigen prediction model
Clinical Research (Excluding Clinical Trials)·2019
Anti-angiogenic activity of PSA-derived peptides
The Prostate·2015· 6 cited
Enzymatic activity of free‐prostate‐specific antigen (f‐PSA) is not required for some of its physiological activities
The Prostate·2011· 12 cited
Cloning and characterization of XiR1, a locus responsible for dagger nematode resistance in grape
Theoretical and Applied Genetics·2010· 37 citedOpen Access
Genetic and QTL analysis of resistance to Xiphinema index in a grapevine cross
Theoretical and Applied Genetics·2007· 74 cited
FTY720, a fungus metabolite, inhibits invasion ability of androgen independent prostate cancer cells through inactivation of RhoA-GTPase
Cancer Research·2005· 1 cited

Frequent Co-authors

Karin Jooss(9), Christine D. Palmer(6), Meghan G. Hart(6), Andrew R. Ferguson(5), Alexis Mantilla(5), Sonia Kounlavouth(4), Desiree Schenk(4), Alexander I. Spira(4), Brian S. Henick(4), Raphaël F. Rousseau(4), Chih‐Yi Liao(4), Ankur Dhanik(4), Amy Rappaport(3), Aaron Yang(3), Mojca Škoberne(3), Jason R. Jaroslavsky(3), Sameek Roychowdhury(3), Benjamin Solomon(3), Roman Yelensky(3), Daniel V.T. Catenacci(3)